Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer

NCT07475403 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer
Liquid Biopsy
Immunotherapy

Interventions

DRUG: Systemic immunotherapy

Sponsor

Tianjin Medical University Second Hospital